MTAP protein status is highly concordant with <i>CDKN2A</i> fluorescent <i>in situ</i> hybridization and allows stratification of the luminal subtype in muscle‐invasive bladder cancer
Our findings highlight CDKN2A HD and MTAP loss as prevalent genetic alterations in MIBC and mUC, particularly within the luminal-URO subtype and FGFR3-mutated, p53-normal/wildtype tumours. MTAP IHC can serve as a surrogate marker for 9p21.3 HD, highlighting its clinical relevance and potential as a therapeutic target and predictive biomarker in MIBC.
Authors
- Elzbieta Slodkowska
- Kenneth J. Craddock (ORCID: https://orcid.org/0000-0001-9702-0830)
- Alexander Oberc (ORCID: https://orcid.org/0000-0001-5024-7974)
- Christopher Sherman (ORCID: https://orcid.org/0000-0003-3550-0657)
- Ekaterina Olkhov‐Mitsel (ORCID: https://orcid.org/0000-0001-7945-7801)
- Michelle R. Downes (ORCID: https://orcid.org/0000-0002-4528-3724)
Institutions
- Sunnybrook Health Science Centre (CA)
- University of Toronto (CA)
- Health Sciences Centre (CA)
Publication Details
- Journal
- Histopathology
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1111/his.15324
- Citations
- 7
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.01